Legal & General Group
VIRX

Legal & General Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Legal & General Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,098
Closed -$15K – 3688
2022
Q1 		$15K Hold
3,098
– – ﹤0.01% 3311
2021
Q4 		$11K Hold
3,098
– – ﹤0.01% 3448
2021
Q3 		$25K Hold
3,098
– – ﹤0.01% 3201
2021
Q2 		$35K Buy
+3,098
New +$31.1K ﹤0.01% 3077
2015
Q2 		– Sell
-45
Closed -$24K – 2785
2015
Q1 		$24K Hold
45
– – ﹤0.01% 2695
2014
Q4 		$24K Hold
45
– – ﹤0.01% 2617
2014
Q3 		$69K Buy
+45
New +$65.1K ﹤0.01% 2177

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Legal & General Group's VIRX Position: Q2 2022 in Review

Legal & General Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2022, closing a stake of 3,098 shares — an estimated $15K sold.

Legal & General Group first reported a position in VIRX in Q3 2014 and held it in 7 quarters. The position peaked at $69K in Q3 2014. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2022.

  • Legal & General Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 3,098 Viracta Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $15K.
  • Legal & General Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2014 and held it in 7 quarters.
  • Legal & General Group's Viracta Therapeutics, Inc. Common Stock position peaked at $69K in Q3 2014.
  • 63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.